Blocking Cell Adaptation May Enhance Leukemia Therapy, Thomas Jefferson University Study
MedPage Today -- HOUSTON, April 14 -- The cell-killing potential of imatinib (Gleevec) increased by 50% to 75% when chloroquine was combined with the tyrosine kinase inhibitor, laboratory studies showed.